Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Paclitaxel+Reparixin
Sponsor: Dompé Farmaceutici S.p.A
Collaborators: PRA Health Sciences